PDS Biotech Submits Amended Protocol for VERSATILE-003 Trial, Potentially Accelerating PDS0101 Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Newsfilter
- Clinical Trial Advancement: PDS Biotech has submitted an amended protocol to the FDA for the VERSATILE-003 trial, aiming to change the progression-free survival (PFS) endpoint to a primary measure, potentially accelerating the approval process for PDS0101 and enhancing the company's competitive position in cancer immunotherapy.
- FDA Meeting Outcomes: The submission follows a constructive meeting with the FDA in December 2025, where the accelerated approval pathway for PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer was discussed, reflecting strong communication with regulators and boosting investor confidence.
- Clinical Data Support: Positive final results from the VERSATILE-002 trial provide data backing for this amendment, demonstrating promising median overall survival (mOS) and durable PFS, which may attract additional investment by validating the therapeutic potential of PDS0101.
- Clear Strategic Goals: CEO Frank Bedu-Addo, PhD, stated that the amendment retains mOS and safety as requirements for full FDA approval while offering a significant opportunity to shorten the duration of VERSATILE-003, highlighting the company's long-term strategic positioning in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PDSB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PDSB
Wall Street analysts forecast PDSB stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.160
Low
3.00
Averages
9.00
High
15.00
Current: 1.160
Low
3.00
Averages
9.00
High
15.00
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PDS Biotechnology Q1 2026 Earnings Call Insights
- Clinical Trial Progress: PDS Biotechnology focused on advancing clinical programs in Q1 2026, with CMO Dr. Kirk Shepard noting an amendment to the VERSATILE-003 study design that incorporates progression-free survival as an interim primary endpoint, which is expected to facilitate a more efficient approval pathway and reduce overall costs.
- Enhanced Patent Protection: The new U.S. patent for PDS0101, combined with anticipated biologics exclusivity, extends market protection into the 2040s, strengthening its competitive position in the HPV16-positive head and neck cancer market.
- Financial Performance: As of March 31, 2026, PDS Biotechnology reported a net loss of approximately $7.3 million, or $0.13 per share, with R&D expenses at $3.5 million and total operating expenses at $6.5 million, indicating a continued commitment to R&D investment.
- Future Outlook: Management anticipates additional patient data on colorectal cancer studies by year-end, while emphasizing alignment with the FDA and plans to restart VERSATILE-003 enrollment in the near future, reflecting confidence in clinical advancements.
See More
PDS Biotechnology Reports Q1 Earnings Results
- Earnings Performance: PDS Biotechnology reported a Q1 GAAP EPS of -$0.13, indicating ongoing challenges in profitability that may affect investor confidence and stock performance.
- Cash Reserves: As of March 31, 2026, the company had a cash balance of $21.7 million, which, while providing some liquidity, raises concerns about the sustainability of operational funding and future investment capabilities.
- Regulatory Progress: Following the amendment of the VERSATILE-003 protocol, PDS Biotechnology outlined an accelerated regulatory timeline, demonstrating a proactive approach to product development and market access that could pave the way for future revenue growth.
- Market Attention: With the financial performance and regulatory advancements of PDS Biotechnology, market interest in the company's future prospects is increasing, prompting investors to closely monitor subsequent financial and operational developments.
See More
PDS Biotechnology to Announce Q1 Earnings on May 13
- Earnings Announcement Date: PDS Biotechnology is set to release its Q1 earnings report on May 13 before the market opens, with investors keenly awaiting the financial results to assess the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.14, reflecting a 33.3% year-over-year improvement, indicating that while still negative, the company shows signs of improving profitability.
- Revenue Forecast: The revenue estimate for the first quarter is projected at $0, highlighting ongoing challenges in revenue generation, which may affect investor confidence in the company's growth prospects.
- Estimate Revision Trends: Over the past three months, there has been one upward revision and no downward adjustments to EPS estimates, suggesting a cautiously optimistic outlook from analysts that could influence stock price movements.
See More
PDS Biotechnology Reports Positive Phase 2 Results for Cancer Therapy
- Clinical Trial Results: PDS Biotechnology's Phase 2 trial led by NCI shows a 77.8% objective response rate for its IL-12 immunocytokine PDS01ADC in metastatic colorectal cancer, significantly outperforming the 35% rate in the control group, indicating strong efficacy.
- Survival Rate Improvement: The two-year survival rate for patients reached approximately 85%, compared to 40% in the control group, suggesting that PDS01ADC could significantly enhance patient survival and potentially redefine treatment standards.
- Progression-Free Survival: With a median follow-up of 13.1 months, the median progression-free survival has not yet been reached, indicating potential long-term efficacy, especially when compared to the control group's 8.1 months, highlighting a promising treatment outlook.
- Innovative Treatment Mechanism: PDS01ADC combines subcutaneous administration with hepatic artery infusion of FUDR to concentrate IL-12 at tumor sites, enhancing anti-tumor potency and tolerability, which may provide new avenues for cancer treatment in the future.
See More
PDS Biotechnology's Cancer Therapy Trial Shows Promising Results
- Clinical Trial Results: PDS Biotechnology's PDS01ADC achieved an objective response rate (ORR) of nearly 78% in a Phase 2 trial for patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases, significantly outperforming the 35% ORR seen in a similar trial without the drug, indicating strong efficacy.
- Survival Rate Improvement: The trial reported a two-year survival rate exceeding 80%, more than double the 35% to 40% survival rate of the comparison group, suggesting that this therapy could significantly enhance patient outcomes and potentially redefine treatment standards.
- Positive Stock Reaction: Following the trial results announcement, PDS Biotechnology's shares surged 24% on Wednesday, reaching their highest levels since August 27, 2025, reflecting strong market confidence in the new therapy and positive investor sentiment.
- Future Development Prospects: The company also updated its Phase 3 VERSATILE-003 trial last month by adding progression-free survival as a primary endpoint, which could expedite the approval of PDS0101 for HPV16-related head and neck cancer, further enhancing market expectations for its future growth.
See More
PDS Biotechnology Reports 2025 Financial Results with Strategic Developments
- Financial Performance: PDS Biotechnology reported a net loss of $34.5 million for 2025, translating to a basic and diluted loss of $0.74 per share, indicating ongoing financial challenges despite a reduction from the previous year's loss of $37.6 million.
- R&D Expenses: The company incurred $19 million in research and development expenses in 2025, down from $22.6 million in 2024, reflecting the significant costs associated with advancing clinical trials, yet future spending trends remain a concern.
- Cash Position: As of December 31, 2025, PDSB's cash balance stood at $26.7 million, which may limit its financial flexibility moving forward, particularly as further investments in R&D are anticipated.
- Clinical Advancements: PDS Biotechnology has made significant progress with the amendment of the VERSATILE-003 trial, which is expected to lead to a more efficient path to accelerated approval, although uncertainties regarding the exact enrollment targets and sample size persist.
See More
PDS Biotechnology Q1 2026 Earnings Call Insights
- Clinical Trial Progress: PDS Biotechnology focused on advancing clinical programs in Q1 2026, with CMO Dr. Kirk Shepard noting an amendment to the VERSATILE-003 study design that incorporates progression-free survival as an interim primary endpoint, which is expected to facilitate a more efficient approval pathway and reduce overall costs.
- Enhanced Patent Protection: The new U.S. patent for PDS0101, combined with anticipated biologics exclusivity, extends market protection into the 2040s, strengthening its competitive position in the HPV16-positive head and neck cancer market.
- Financial Performance: As of March 31, 2026, PDS Biotechnology reported a net loss of approximately $7.3 million, or $0.13 per share, with R&D expenses at $3.5 million and total operating expenses at $6.5 million, indicating a continued commitment to R&D investment.
- Future Outlook: Management anticipates additional patient data on colorectal cancer studies by year-end, while emphasizing alignment with the FDA and plans to restart VERSATILE-003 enrollment in the near future, reflecting confidence in clinical advancements.
See More
PDS Biotechnology Reports Q1 Earnings Results
- Earnings Performance: PDS Biotechnology reported a Q1 GAAP EPS of -$0.13, indicating ongoing challenges in profitability that may affect investor confidence and stock performance.
- Cash Reserves: As of March 31, 2026, the company had a cash balance of $21.7 million, which, while providing some liquidity, raises concerns about the sustainability of operational funding and future investment capabilities.
- Regulatory Progress: Following the amendment of the VERSATILE-003 protocol, PDS Biotechnology outlined an accelerated regulatory timeline, demonstrating a proactive approach to product development and market access that could pave the way for future revenue growth.
- Market Attention: With the financial performance and regulatory advancements of PDS Biotechnology, market interest in the company's future prospects is increasing, prompting investors to closely monitor subsequent financial and operational developments.
See More
PDS Biotechnology to Announce Q1 Earnings on May 13
- Earnings Announcement Date: PDS Biotechnology is set to release its Q1 earnings report on May 13 before the market opens, with investors keenly awaiting the financial results to assess the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.14, reflecting a 33.3% year-over-year improvement, indicating that while still negative, the company shows signs of improving profitability.
- Revenue Forecast: The revenue estimate for the first quarter is projected at $0, highlighting ongoing challenges in revenue generation, which may affect investor confidence in the company's growth prospects.
- Estimate Revision Trends: Over the past three months, there has been one upward revision and no downward adjustments to EPS estimates, suggesting a cautiously optimistic outlook from analysts that could influence stock price movements.
See More
PDS Biotechnology Reports Positive Phase 2 Results for Cancer Therapy
- Clinical Trial Results: PDS Biotechnology's Phase 2 trial led by NCI shows a 77.8% objective response rate for its IL-12 immunocytokine PDS01ADC in metastatic colorectal cancer, significantly outperforming the 35% rate in the control group, indicating strong efficacy.
- Survival Rate Improvement: The two-year survival rate for patients reached approximately 85%, compared to 40% in the control group, suggesting that PDS01ADC could significantly enhance patient survival and potentially redefine treatment standards.
- Progression-Free Survival: With a median follow-up of 13.1 months, the median progression-free survival has not yet been reached, indicating potential long-term efficacy, especially when compared to the control group's 8.1 months, highlighting a promising treatment outlook.
- Innovative Treatment Mechanism: PDS01ADC combines subcutaneous administration with hepatic artery infusion of FUDR to concentrate IL-12 at tumor sites, enhancing anti-tumor potency and tolerability, which may provide new avenues for cancer treatment in the future.
See More
PDS Biotechnology's Cancer Therapy Trial Shows Promising Results
- Clinical Trial Results: PDS Biotechnology's PDS01ADC achieved an objective response rate (ORR) of nearly 78% in a Phase 2 trial for patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases, significantly outperforming the 35% ORR seen in a similar trial without the drug, indicating strong efficacy.
- Survival Rate Improvement: The trial reported a two-year survival rate exceeding 80%, more than double the 35% to 40% survival rate of the comparison group, suggesting that this therapy could significantly enhance patient outcomes and potentially redefine treatment standards.
- Positive Stock Reaction: Following the trial results announcement, PDS Biotechnology's shares surged 24% on Wednesday, reaching their highest levels since August 27, 2025, reflecting strong market confidence in the new therapy and positive investor sentiment.
- Future Development Prospects: The company also updated its Phase 3 VERSATILE-003 trial last month by adding progression-free survival as a primary endpoint, which could expedite the approval of PDS0101 for HPV16-related head and neck cancer, further enhancing market expectations for its future growth.
See More
PDS Biotechnology Reports 2025 Financial Results with Strategic Developments
- Financial Performance: PDS Biotechnology reported a net loss of $34.5 million for 2025, translating to a basic and diluted loss of $0.74 per share, indicating ongoing financial challenges despite a reduction from the previous year's loss of $37.6 million.
- R&D Expenses: The company incurred $19 million in research and development expenses in 2025, down from $22.6 million in 2024, reflecting the significant costs associated with advancing clinical trials, yet future spending trends remain a concern.
- Cash Position: As of December 31, 2025, PDSB's cash balance stood at $26.7 million, which may limit its financial flexibility moving forward, particularly as further investments in R&D are anticipated.
- Clinical Advancements: PDS Biotechnology has made significant progress with the amendment of the VERSATILE-003 trial, which is expected to lead to a more efficient path to accelerated approval, although uncertainties regarding the exact enrollment targets and sample size persist.
See More
